Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
ALX Oncology Holdings Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 1.89 · gapped above the open, then crossed back over prior close. High/low 1.90 at 9:30 am ET, 1.86 at 1:15 pm ET.
ALX Oncology Holdings Inc has 20 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either ALX Oncology Holdings Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of ALX Oncology Holdings Inc. Customers appear here when ALX Oncology Holdings Inc names them, or when a company names ALX Oncology Holdings Inc as a supplier in its own annual report.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“For instance, we entered into clinical trial collaboration and supply agreements with Eli Lilly, pursuant to which our collaboration counterparties will supply doses of ramucirumab for use in certain clinical trials.”
FILING10-K0001193125-26-098454cik 0001810182
“o Our collaborator, Jazz Pharmaceuticals plc (Jazz), sponsored and managed the Phase 1b/2 trial of zanidatamab, a HER2-targeted anti-cancer antibody, for the treatment of advanced HER2-expressing breast cancer and other solid tumors in combination with evorpacept (Zanidatamab Trial).”
FILING10-K0001193125-26-098454cik 0001810182
“o In April 2023, we announced a collaboration with Sanofi who will sponsor and manage a Phase 1/2 trial of SARCLISA ® (isatuximab-irfc), an anti-cancer antibody, and dexamethasone in combination with evorpacept for the treatment of patients with relapsed or refractory multiple myeloma.”
FILING10-K0001193125-26-098454cik 0001810182
“We obtained a worldwide, royalty-bearing, sublicensable license from the Board of Trustees of the Leland Stanford Junior University, or Stanford, under certain patents relating to high-affinity SIRPα variant polypeptides, to develop, manufacture and commercialize products for use in certain licensed fields, the scope of which would include the application of the licensed intellectual property in oncology.”
FILING10-K0001193125-26-098454cik 0001810182
“We first entered into an engagement with KBI Biopharma, Inc. in 2015 for evorpacept analytical method development, formulation development, bulk drug manufacturing, release and stability testing.”
FILING10-K0001193125-26-098454cik 0001810182
“We first entered into a drug product manufacturing agreement with Lyophilization Services of New England, Inc. (now PCI Pharma Services) in 2016 for evorpacept drug product used in clinical trials.”
FILING10-K0001193125-26-098454cik 0001810182
“o In 2021, an IST of evorpacept was initiated in combination with rituximab and lenalidomide (R 2 ) for the treatment of patients with indolent and aggressive NHL, sponsored by MD Anderson Cancer Center in Texas.”
FILING10-K0001193125-26-098454cik 0001810182
“We first entered into an engagement with Patheon Biologics LLC in 2022 for evorpacept bulk drug manufacturing and release testing.”
FILING10-K0001193125-26-098454cik 0001810182
“We subsequently entered into a drug product manufacturing agreement with Patheon UK Limited in 2022 for drug product production of evorpacept drug product used in clinical trials.”
FILING10-K0001193125-26-098454cik 0001810182
“We first entered into an engagement with WuXi Biologics and WuXi XDC in 2023 for ALX2004 analytical method development, formulation development, bulk drug manufacturing, drug product manufacturing, release and stability testing, used in clinical trials.”
FILING10-K0001193125-26-098454cik 0001810182
“We first entered into an engagement with WuXi Biologics and WuXi XDC in 2023 for ALX2004 analytical method development, formulation development, bulk drug manufacturing, drug product manufacturing, release and stability testing, used in clinical trials.”
FILING10-K0001193125-26-098454cik 0001810182
“In December 2021, we entered into a sales agreement (as amended, Sales Agreement) with Cantor Fitzgerald & Co. and Credit Suisse Securities (USA) LLC (Credit Suisse), under which we may offer and sell our common stock, having aggregate gross proceeds of up to $150.0 million, from time to time through them as our sales agents in our ATM offering program.”
FILING10-K0001193125-26-098454cik 0001810182
“In December 2021, we entered into a sales agreement (as amended, Sales Agreement) with Cantor Fitzgerald & Co. and Credit Suisse Securities (USA) LLC (Credit Suisse), under which we may offer and sell our common stock, having aggregate gross proceeds of up to $150.0 million, from time to time through them as our sales agents in our ATM offering program.”
FILING10-K0001193125-26-098454cik 0001810182
“In August 2023, we entered into an amendment to the Sales Agreement to include UBS Securities LLC as an additional sales agent and to remove Credit Suisse as a sales agent.”
FILING10-K0001193125-26-098454cik 0001810182
“o Our initial collaborator for the Zanidatamab Trial was Zymeworks Inc. (Zymeworks), however in a series of transactions commencing in October 2022, Jazz assumed responsibility from Zymeworks for the development and commercialization of zanidatamab in the United States, Europe, Japan and certain other territories, including responsibility for the Zanidatamab Trial.”
FILING10-K0001193125-26-098454cik 0001810182
“While we have cash in operating accounts with SVB, the majority of our cash, cash equivalents and investments are deposited in custodial accounts held by U.S. Bank for which SVB Asset Management is the investment advisor.”
FILING10-K0001193125-26-098454cik 0001810182
“Under the Loan Agreement, 50% of the funding comes from SVB, one of the three Lenders.”
FILING10-K0001193125-26-098454cik 0001810182
“While we have cash in operating accounts with SVB, the majority of our cash, cash equivalents and investments are deposited in custodial accounts held by U.S. Bank for which SVB Asset Management is the investment advisor.”
FILING10-K0001193125-26-098454cik 0001810182
“Given the SVBB acquisition by First Citizens Bank, SVB-First Citizens will continue to fulfill SVB's obligations under the Loan Agreement.”
FILING10-K0001193125-26-098454cik 0001810182
“We maintain the confidentiality of trade secrets and proprietary information in part by entering into confidentiality agreements with our employees, consultants, other service providers, including former service provider Tallac Therapeutics, strategic partners and others upon the commencement of their relationships with us.”
FILING10-K0001193125-26-098454cik 0001810182
Watchlist prices, news filtered to it, and its next report on your desk.
ALXO (ALX Oncology Holdings Inc) has 20 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: UBS −2.92%, in the industrials bundle.